title: Insulin-like growth factor-1 lowers protein oxidation in patients with thermal injury.
abstract: OBJECTIVE
  The effect of insulin-like growth factor-1 (IGF-1) on energy expenditure and protein and glucose metabolism in a group of patients with thermal injury was determined.
  
  
  BACKGROUND
  Accelerated protein catabolism is a constant feature of the hypermetabolic response to thermal injury. Insulin-like growth factor-1 has been reported to minimize protein catabolism and normalize energy expenditure in animal models of thermal injury.
  
  
  METHODS
  To determine the efficacy of IGF-1 in human burn patients, resting energy expenditure (metabolic cart), whole body protein kinetics (N15 Lysine), and glucose disposal (glucose tolerance test) were assessed in eight burn patients before and after a 3-day infusion of IGF-1 (20 micrograms/kg/hr). All patients were fluid-resuscitated uneventfully and were without obvious infection at the time of study. Enteral nutrition was administered at a constant rate before and during the IGF-1 infusion.
  
  
  RESULTS
  Resting energy expenditure was not altered by IGF-1 (40.3 +/- 2.2 vs. 39.1 +/- 2.3 kcal/kg/day). However, glucose uptake was promoted, and protein oxidation decreased significantly (0.118 +/- 0.029 vs. 0.087 +/- 0.021 g/kg/d, p < 0.05) by IGF-1. In addition, insulin secretion, in response to a glucose challenge, was blunted.
  
  
  CONCLUSIONS
  Insulin-like growth factor-1 therapy has a beneficial effect in preserving lean body mass during severe stress conditions by minimizing the flux of amino acids toward oxidation.
authors.affiliation: U.S. Army Institute of Surgical Research, Fort Sam Houston, Texas.
authors.forename: W G
authors.initials: WG
authors.lastname: Cioffi
authors.forename: D C
authors.initials: DC
authors.lastname: Gore
authors.forename: L W
authors.initials: LW
authors.lastname: Rue
authors.forename: G
authors.initials: G
authors.lastname: Carrougher
authors.forename: H P
authors.initials: HP
authors.lastname: Guler
authors.forename: W F
authors.initials: WF
authors.lastname: McManus
authors.forename: B A
authors.initials: BA
authors.lastname: Pruitt
mesh_terms: D000328:Adult; D002056:Burns / Q000188:drug therapy / Q000378:metabolism*; D004734:Energy Metabolism / Q000187:drug effects*; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D007262:Infusions, Intravenous; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D010084:Oxidation-Reduction; D011506:Proteins / Q000187:drug effects / Q000378:metabolism*
chemical_list: D011506:Proteins; D007334:Insulin-Like Growth Factor I; D005947:Glucose